172 related articles for article (PubMed ID: 24375440)
61. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
62. The transcription factor sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (SPDEF) is required for E-cadherin expression in prostate cancer cells.
Pal M; Koul S; Koul HK
J Biol Chem; 2013 Apr; 288(17):12222-31. PubMed ID: 23449978
[TBL] [Abstract][Full Text] [Related]
63. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
64. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
65. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
Sekino Y; Oue N; Mukai S; Shigematsu Y; Goto K; Sakamoto N; Sentani K; Hayashi T; Teishima J; Matsubara A; Yasui W
Prostate; 2019 Feb; 79(2):234-242. PubMed ID: 30324761
[TBL] [Abstract][Full Text] [Related]
66. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
Rigatti P; Scattoni V
Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
[No Abstract] [Full Text] [Related]
67. Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer.
Fuzio P; Lucarelli G; Perlino E; Battaglia M; Bettocchi C; Selvaggi FP; Ditonno P
Oncol Rep; 2009 Aug; 22(2):327-35. PubMed ID: 19578773
[TBL] [Abstract][Full Text] [Related]
68. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
69. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
[TBL] [Abstract][Full Text] [Related]
70. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
71. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
72. Targeting the androgen receptor in prostate cancer.
Culig Z
Expert Opin Pharmacother; 2014 Jul; 15(10):1427-37. PubMed ID: 24890318
[TBL] [Abstract][Full Text] [Related]
73. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
[TBL] [Abstract][Full Text] [Related]
74. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
[TBL] [Abstract][Full Text] [Related]
75. Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.
Akyol F; Selek U; Ozyigit G; Onal C; Akdogan B; Karabulut E; Ozen H
J Natl Med Assoc; 2006 Jul; 98(7):1058-61. PubMed ID: 16895273
[TBL] [Abstract][Full Text] [Related]
76. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
[TBL] [Abstract][Full Text] [Related]
77. The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
Khriguian J; Tsui JMG; Vaughan R; Kucharczyk MJ; Nabid A; Bettahar R; Vincent L; Martin AG; Jolicoeur M; Yassa M; Barkati M; Igidbashian L; Bahoric B; Archambault R; Villeneuve H; Mohiuddin M; Niazi T
J Urol; 2021 Jun; 205(6):1648-1654. PubMed ID: 33577365
[TBL] [Abstract][Full Text] [Related]
78. Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program.
Wirth MP; Froehner M
Oncology; 2003; 65 Suppl 1():1-4. PubMed ID: 12949426
[TBL] [Abstract][Full Text] [Related]
79. A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy.
Bryk DJ; Angermeier KW; Klein EA
Urology; 2019 Jul; 129():e4-e5. PubMed ID: 30935936
[TBL] [Abstract][Full Text] [Related]
80. Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.
Washino S; Hirai M; Saito K; Kobayashi Y; Arai Y; Miyagawa T
Low Urin Tract Symptoms; 2018 Jan; 10(1):57-63. PubMed ID: 27943566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
